Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | CDK12 del |
Gene Variant Detail | |
Relevant Treatment Approaches | Olaparib |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
CDK12 del | prostate cancer | sensitive | Olaparib | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of prostate cancer cell lines with biallelic CDK12 truncations in culture (PMID: 39321214). | 39321214 |
CDK12 del | prostate cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of prostate cancer cell lines with biallelic CDK12 truncations in culture (PMID: 39321214). | 39321214 | |
CDK12 del | prostate cancer | sensitive | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of a prostate cancer cell line with biallelic CDK12 truncations in culture (PMID: 39321214). | 39321214 | |
CDK12 del | prostate cancer | sensitive | Rucaparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Rubraca (rucaparib) treatment inhibited viability of prostate cancer cell lines with biallelic CDK12 truncations in culture and inhibited tumor growth in a cell line xenograft model (PMID: 39321214). | 39321214 |